Nuvelo, Inc. NUVO - Nuvelo Announces Presentation of rNAPc2 Phase 2 Efficacy Data at World Congress of Cardiology 2006
Nuvelo, Inc. NUVO - Nuvelo Announces Presentation of rNAPc2 Phase 2 Efficacy Data at World Congress of Cardiology 2006
--Nuvelo to Host Conference Call on Tuesday, September 5th at 4:30 p.m.
EDT--
SAN CARLOS, Calif., Aug. 29 /PRNewswire/ -- Nuvelo, Inc. (Nasdaq: NUVO)
today announced that new data from the ANTHEM (Anticoagulation with rNAPc2
To Help Eliminate MACE)/TIMI 32 trial evaluating recombinant nematode
anticoagulant protein c2 (rNAPc2) in patients with acute coronary syndromes
(ACS) will be presented at the World Congress of Cardiology 2006 taking
place from September 2nd through the 5th in Barcelona, Spain. Nuvelo
management will host a conference call to present and discuss the data on
Tuesday, September 5th at 4:30 p.m. EDT.
The presentation details are as follows:
Poster Session (Program #3897): "Tissue-factor/factor VIIa inhibition
with higher-dose rNAPc2 reduces ischemia in patients with NSTE-ACS managed
with an early invasive strategy in ANTHEM-TIMI 32"
Date/Time: Tuesday, September 5, 2006, 8:30 - 12:30 a.m. CEST
Presenter: Robert P. Giugliano, M.D., S.M., investigator, TIMI Study
Group, associate physician, Brigham and Women's Hospital and assistant
professor of medicine, Harvard Medical School
Conference Call Information
Nuvelo will hold a conference call on September 5, 2006 at 4:30 p.m.
Eastern Time to discuss the data presentation. Speakers will include Steven
Deitcher, M.D., vice president and chief medical scientist and Ted W. Love,
M.D., chairman and chief executive officer. To participate in the
conference call, please dial 866-713-8567 for domestic callers and
617-597-5326 for international callers and reference conference passcode,
21826949. A telephone replay of the conference call will be available
through Tuesday, September 12, 2006. To access the replay, please dial
888-286-8010 for domestic callers and 617-801-6888 for international
callers and reference conference passcode, 96057794.
This call is also being webcast by Thomson/CCBN and can be accessed at
Nuvelo's website at http://www.nuvelo.com or by visiting Thomson/CCBN's
StreetEvents Network. Individual investors can listen to the call at
http://www.earnings.com, Thomson's individual investor portal, powered by
StreetEvents. Institutional investors can access the call via Thomson
StreetEvents (http://www.streetevents.com), a password-protected event management
site.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through
the discovery, development and commercialization of novel drugs for acute
cardiovascular and cancer therapy. Nuvelo's development pipeline includes
three acute cardiovascular programs: alfimeprase, a direct-acting
thrombolytic in four Phase 3 clinical trials for the treatment of
thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the
factor VIIa and tissue factor protease complex which recently completed
Phase 2 clinical development in acute coronary syndromes; and preclinical
candidate NU172, a direct thrombin inhibitor for use as a short-acting
anticoagulant during medical procedures. Nuvelo is also advancing an
emerging oncology pipeline, which includes NU206 for the potential
treatment of chemotherapy/radiation therapy- induced mucositis, as well as
rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects
to leverage its expertise in secreted proteins and cancer antibody
discovery to further expand its pipeline and create additional partnering
and licensing opportunities.
Please Nominate Arizona Biotech for the Blog of the Day Awards
Biotech
Biotech
--Nuvelo to Host Conference Call on Tuesday, September 5th at 4:30 p.m.
EDT--
SAN CARLOS, Calif., Aug. 29 /PRNewswire/ -- Nuvelo, Inc. (Nasdaq: NUVO)
today announced that new data from the ANTHEM (Anticoagulation with rNAPc2
To Help Eliminate MACE)/TIMI 32 trial evaluating recombinant nematode
anticoagulant protein c2 (rNAPc2) in patients with acute coronary syndromes
(ACS) will be presented at the World Congress of Cardiology 2006 taking
place from September 2nd through the 5th in Barcelona, Spain. Nuvelo
management will host a conference call to present and discuss the data on
Tuesday, September 5th at 4:30 p.m. EDT.
The presentation details are as follows:
Poster Session (Program #3897): "Tissue-factor/factor VIIa inhibition
with higher-dose rNAPc2 reduces ischemia in patients with NSTE-ACS managed
with an early invasive strategy in ANTHEM-TIMI 32"
Date/Time: Tuesday, September 5, 2006, 8:30 - 12:30 a.m. CEST
Presenter: Robert P. Giugliano, M.D., S.M., investigator, TIMI Study
Group, associate physician, Brigham and Women's Hospital and assistant
professor of medicine, Harvard Medical School
Conference Call Information
Nuvelo will hold a conference call on September 5, 2006 at 4:30 p.m.
Eastern Time to discuss the data presentation. Speakers will include Steven
Deitcher, M.D., vice president and chief medical scientist and Ted W. Love,
M.D., chairman and chief executive officer. To participate in the
conference call, please dial 866-713-8567 for domestic callers and
617-597-5326 for international callers and reference conference passcode,
21826949. A telephone replay of the conference call will be available
through Tuesday, September 12, 2006. To access the replay, please dial
888-286-8010 for domestic callers and 617-801-6888 for international
callers and reference conference passcode, 96057794.
This call is also being webcast by Thomson/CCBN and can be accessed at
Nuvelo's website at http://www.nuvelo.com or by visiting Thomson/CCBN's
StreetEvents Network. Individual investors can listen to the call at
http://www.earnings.com, Thomson's individual investor portal, powered by
StreetEvents. Institutional investors can access the call via Thomson
StreetEvents (http://www.streetevents.com), a password-protected event management
site.
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through
the discovery, development and commercialization of novel drugs for acute
cardiovascular and cancer therapy. Nuvelo's development pipeline includes
three acute cardiovascular programs: alfimeprase, a direct-acting
thrombolytic in four Phase 3 clinical trials for the treatment of
thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the
factor VIIa and tissue factor protease complex which recently completed
Phase 2 clinical development in acute coronary syndromes; and preclinical
candidate NU172, a direct thrombin inhibitor for use as a short-acting
anticoagulant during medical procedures. Nuvelo is also advancing an
emerging oncology pipeline, which includes NU206 for the potential
treatment of chemotherapy/radiation therapy- induced mucositis, as well as
rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects
to leverage its expertise in secreted proteins and cancer antibody
discovery to further expand its pipeline and create additional partnering
and licensing opportunities.
Please Nominate Arizona Biotech for the Blog of the Day Awards
Biotech
Biotech
posted by Bill Austin - Nuvelo, Inc. NUVO - Nuvelo Announces Presentation of rNAPc2 Phase 2 Efficacy Data at World Congress of Cardiology 2006
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home